Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Natera, Inc. - Common Stock
(NQ:
NTRA
)
231.25
-9.09 (-3.78%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Natera, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Natera Announces Medicare Coverage for Signatera™ Genome
June 04, 2025
From
Natera, Inc.
Via
Business Wire
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
June 02, 2025
From
Natera, Inc.
Via
Business Wire
2 Cash-Heavy Stocks for Long-Term Investors and 1 to Be Wary Of
June 02, 2025
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...
Via
StockStory
3 Mid-Cap Stocks Worth Your Attention
May 27, 2025
Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses...
Via
StockStory
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
Preview: Natera's Earnings
↗
May 07, 2025
Via
Benzinga
Peering Into Natera's Recent Short Interest
↗
May 02, 2025
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
↗
May 26, 2025
Via
Benzinga
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
May 22, 2025
From
Natera, Inc.
Via
Business Wire
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
↗
May 12, 2025
Via
Benzinga
8 Analysts Have This To Say About Natera
↗
May 09, 2025
Via
Benzinga
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales
May 08, 2025
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98...
Via
StockStory
Natera Reports First Quarter 2025 Financial Results
May 08, 2025
From
Natera, Inc.
Via
Business Wire
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
May 08, 2025
From
Natera, Inc.
Via
Business Wire
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
May 07, 2025
From
Natera, Inc.
Via
Business Wire
What To Expect From Natera’s (NTRA) Q1 Earnings
May 07, 2025
Genetic testing company Natera (NASDAQ:NTRA). will be reporting earnings tomorrow after market hours. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera
May 05, 2025
From
Natera, Inc.
Via
Business Wire
Natera to Report its First Quarter Results on May 8, 2025
May 01, 2025
From
Natera, Inc.
Via
Business Wire
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
April 29, 2025
From
Natera, Inc.
Via
Business Wire
2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of
April 29, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...
Via
StockStory
Topics
Stocks
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
↗
April 28, 2025
Via
Benzinga
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test
April 24, 2025
From
Natera, Inc.
Via
Business Wire
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
April 22, 2025
From
Natera, Inc.
Via
Business Wire
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 to Turn Down
April 18, 2025
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...
Via
StockStory
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
↗
April 17, 2025
Via
Benzinga
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
↗
April 17, 2025
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Via
Investor's Business Daily
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
April 15, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
April 14, 2025
Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Assessing Natera: Insights From 10 Financial Analysts
↗
April 10, 2025
Via
Benzinga
3 Reasons NTRA Has Explosive Upside Potential
April 08, 2025
Natera currently trades at $141.03 and has been a dream stock for shareholders. It’s returned 351% since April 2020, blowing past the S&P 500’s 87.1% gain. The company has also beaten the index over...
Via
StockStory
Topics
Government
Stocks
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
